$CUE News

Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response

Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?

Cue Biopharma, Inc. (CUE) Discusses Positive Phase II Top Line Results for CUE-221 in Chronic Spontaneous Urticaria - Slideshow

Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results

What's Going on With Cue Biopharma Stock on Monday?

Reported Sunday, Cue Biopharma's CUE-221 Shows 60% Complete Hives Resolution Twelve Weeks Off Treatment At 4 Mg/Kg In Phase 2 Chronic Spontaneous Urticaria Study Versus 24% For Omalizumab In Post Hoc Analysis

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

B. Riley Securities Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $83

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Cue Biopharma Q2 EPS $(24.14) Misses $(1.69) Estimate, Sales $7.877M Beat $3.000M Estimate

Cue Biopharma Files Prospectus For Resale Of 1,505,570 Shares, Including 87,500 Underlying Pre-Funded Warrants, Issued In $50M July Private Placement

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission

Cue Biopharma Appoints James M. Ahlers CFO

Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development

Cue: The Market Is Paying $86M For A Drug It Doesn't Own

Cue Biopharma Announces $50.0 Million Private Placement

Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution

Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference

Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments

Cue Biopharma Q1 EPS $(1.08) Misses $(0.10) Estimate, Sales $5.686M Beat $1.875M Estimate